Edward Zecchini Sells 33,600 Shares of CryoPort (NASDAQ:CYRX) Stock

CryoPort, Inc. (NASDAQ:CYRX) insider Edward Zecchini sold 33,600 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $14.47, for a total value of $486,192.00. Following the completion of the transaction, the insider directly owned 109,719 shares of the company’s stock, valued at approximately $1,587,633.93. The trade was a 23.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

CryoPort Price Performance

CYRX stock opened at $14.62 on Friday. The business has a fifty day moving average price of $12.42 and a 200 day moving average price of $10.33. CryoPort, Inc. has a fifty-two week low of $6.16 and a fifty-two week high of $16.73. The stock has a market capitalization of $736.88 million, a price-to-earnings ratio of 10.83 and a beta of 1.90.

CryoPort (NASDAQ:CYRX) last released its quarterly earnings results on Monday, May 4th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). CryoPort had a net margin of 41.57% and a negative return on equity of 7.92%. The business had revenue of $47.80 million for the quarter, compared to analyst estimates of $44.86 million. On average, equities analysts expect that CryoPort, Inc. will post -0.85 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Empire Financial Management Company LLC boosted its position in CryoPort by 24.4% in the 1st quarter. Empire Financial Management Company LLC now owns 502,575 shares of the company’s stock valued at $4,161,000 after buying an additional 98,714 shares during the last quarter. Quantinno Capital Management LP boosted its position in shares of CryoPort by 30.7% in the 1st quarter. Quantinno Capital Management LP now owns 43,966 shares of the company’s stock worth $364,000 after purchasing an additional 10,337 shares during the last quarter. Granahan Investment Management LLC boosted its position in shares of CryoPort by 475.0% in the 1st quarter. Granahan Investment Management LLC now owns 231,138 shares of the company’s stock worth $1,914,000 after purchasing an additional 190,938 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of CryoPort by 62.9% in the 1st quarter. Renaissance Technologies LLC now owns 368,110 shares of the company’s stock worth $3,048,000 after purchasing an additional 142,070 shares during the last quarter. Finally, State of Wyoming boosted its position in shares of CryoPort by 9.4% in the 1st quarter. State of Wyoming now owns 42,520 shares of the company’s stock worth $352,000 after purchasing an additional 3,638 shares during the last quarter. 92.90% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Craig Hallum raised their price target on CryoPort from $15.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, June 3rd. Jefferies Financial Group set a $13.50 price target on CryoPort in a report on Monday, June 8th. KeyCorp raised their price target on CryoPort from $15.00 to $17.00 and gave the company an “overweight” rating in a report on Wednesday, May 20th. Weiss Ratings raised CryoPort from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, May 6th. Finally, Wall Street Zen raised CryoPort from a “sell” rating to a “hold” rating in a report on Monday, May 11th. Eight investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, CryoPort has an average rating of “Moderate Buy” and an average price target of $15.11.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.